ES2526338T3 - Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad - Google Patents

Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad Download PDF

Info

Publication number
ES2526338T3
ES2526338T3 ES08741448.8T ES08741448T ES2526338T3 ES 2526338 T3 ES2526338 T3 ES 2526338T3 ES 08741448 T ES08741448 T ES 08741448T ES 2526338 T3 ES2526338 T3 ES 2526338T3
Authority
ES
Spain
Prior art keywords
dpp
obesity
inhibitor
preparation
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08741448.8T
Other languages
English (en)
Spanish (es)
Inventor
Heung Jae Kim
Woo Young Kwak
Chang Yell Shin
Hadong Kim
Jong Pil Min
Kyung Jin Park
Jae Young Lee
Song-Hyen Choi
Tae Hyun Yoon
Hae-Sun Kim
Ji Myun Jang
Mi-Kyung Kim
Moon-Ho Son
Soon Hoe Kim
Moohi Yoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong A Pharmaceutical Co Ltd
Original Assignee
Dong A Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharmaceutical Co Ltd filed Critical Dong A Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2526338T3 publication Critical patent/ES2526338T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08741448.8T 2007-04-19 2008-04-18 Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad Active ES2526338T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070038462 2007-04-19
KR20070038462 2007-04-19
PCT/KR2008/002203 WO2008130151A1 (en) 2007-04-19 2008-04-18 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity

Publications (1)

Publication Number Publication Date
ES2526338T3 true ES2526338T3 (es) 2015-01-09

Family

ID=39875638

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08741448.8T Active ES2526338T3 (es) 2007-04-19 2008-04-18 Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad

Country Status (15)

Country Link
US (1) US8030315B2 (enExample)
EP (1) EP2142519B1 (enExample)
JP (1) JP5148686B2 (enExample)
KR (1) KR101007497B1 (enExample)
CN (2) CN102516184B (enExample)
AU (1) AU2008241692B2 (enExample)
BR (1) BRPI0810246B1 (enExample)
CA (1) CA2683696C (enExample)
ES (1) ES2526338T3 (enExample)
IL (1) IL201524A (enExample)
MX (1) MX2009011276A (enExample)
NZ (1) NZ580701A (enExample)
PT (1) PT2142519E (enExample)
RU (1) RU2419615C1 (enExample)
WO (1) WO2008130151A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
SG174974A1 (en) * 2009-03-30 2011-11-28 Dong A Pharm Co Ltd Improved method for preparing dipeptidyl peptidase-iv inhibitor and intermediate
RU2498976C9 (ru) * 2009-03-30 2014-02-27 Донг-А Фармасьютикал. Ко., Лтд Усовершенствованный способ получения ингибитора дипептидилпептидазы-iv и промежуточного соединения
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110107287A (ko) * 2010-03-24 2011-09-30 동아제약주식회사 비알콜성 지방간 질환의 예방 및 치료용 약학적 조성물
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
KR101290029B1 (ko) 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
CN102321014A (zh) * 2011-05-27 2012-01-18 沈阳亿灵医药科技有限公司 新型双苯基吡啶类衍生物
US20140336196A1 (en) * 2011-05-27 2014-11-13 Merck Sharp & Dohme Corp. Phosphoric acid salts of sitagliptin
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
KR101626653B1 (ko) * 2013-06-26 2016-06-01 동아에스티 주식회사 Ｄｐｐ-ｉｖ 저해제를 함유하는 신장 질환 예방 또는 치료용 조성물
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
KR101709127B1 (ko) 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN107382757A (zh) * 2017-08-11 2017-11-24 苏州信恩医药科技有限公司 不对称烯丙基取代反应在依格列汀中间体合成中的应用
CN107417554A (zh) * 2017-08-15 2017-12-01 苏州信恩医药科技有限公司 一种依格列汀中间体的合成方法
KR20220165346A (ko) 2021-06-08 2022-12-15 동아에스티 주식회사 에보글립틴의 안정성이 개선된 제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100544000B1 (ko) * 2000-05-25 2006-01-20 에프. 호프만-라 로슈 아게 치환된 1-아미노알킬-락탐 및 무스카린성 수용체길항제로서의 용도
BR0111019A (pt) * 2000-05-25 2003-06-17 Hoffmann La Roche 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptores muscarìnicos
JP2002088070A (ja) * 2000-09-18 2002-03-27 Mitsubishi Rayon Co Ltd 新規ピペラジノン誘導体およびその製造方法
JP4491346B2 (ja) * 2002-10-07 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病ベータアミノ複素環ジペプチジルペプチダーゼ阻害剤
EP1556362B1 (en) 2002-10-18 2008-03-26 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7259160B2 (en) 2003-07-31 2007-08-21 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1541143A1 (en) 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
EP1695969A4 (en) 2003-12-11 2008-11-26 Mitsubishi Tanabe Pharma Corp ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE
EP1593671A1 (en) * 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
GB0413389D0 (en) * 2004-06-16 2004-07-21 Astrazeneca Ab Chemical compounds
WO2006104997A2 (en) 2005-03-29 2006-10-05 Merck & Co., Inc. Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor
JP2008031064A (ja) * 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体

Also Published As

Publication number Publication date
CA2683696C (en) 2012-05-22
US20100120790A1 (en) 2010-05-13
EP2142519A1 (en) 2010-01-13
CN102516184A (zh) 2012-06-27
EP2142519A4 (en) 2011-07-13
RU2419615C1 (ru) 2011-05-27
MX2009011276A (es) 2010-01-15
HK1172613A1 (en) 2013-04-26
JP2011500508A (ja) 2011-01-06
JP5148686B2 (ja) 2013-02-20
EP2142519B1 (en) 2014-09-24
WO2008130151A1 (en) 2008-10-30
PT2142519E (pt) 2014-12-11
IL201524A0 (en) 2010-05-31
KR101007497B1 (ko) 2011-01-12
BRPI0810246B1 (pt) 2021-11-30
HK1138272A1 (en) 2010-08-20
CA2683696A1 (en) 2008-10-30
AU2008241692B2 (en) 2011-02-10
CN101663282B (zh) 2012-02-15
BRPI0810246A2 (pt) 2015-08-18
KR20080094604A (ko) 2008-10-23
US8030315B2 (en) 2011-10-04
CN102516184B (zh) 2015-03-25
IL201524A (en) 2014-09-30
CN101663282A (zh) 2010-03-03
NZ580701A (en) 2011-07-29
AU2008241692A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
ES2526338T3 (es) Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CL2021002883A1 (es) Moduladores de thr-ß y métodos de uso de estos
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
ECSP066653A (es) Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad
CR20210426A (es) Compuestos, composiciones y métodos
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
MX2021011647A (es) Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.
AR058901A1 (es) Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende
ECSP10010447A (es) Inhibidores de cinasa pim y métodos para su uso
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
CL2008001671A1 (es) Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes.
AR067770A1 (es) Derivados de tiazol y ditiazol para el tratamiento de diabetes
PE20180412A1 (es) Compuestos inhibidores de la senalizacion de la via de notch
CL2021000196A1 (es) Método de tratamiento de la epilepsia
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
CO6140054A2 (es) Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl